PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`11
`Legal Name
`
`I Remove
`
`I
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`I El t'Jaoki
`
`Residence Information (Select One)
`
`City
`
`[sukuba-shi, lbaraki
`
`I
`US Residency
`
`JlvATANABE
`• Non US Residency
`Active US Military Service
`l1country of Residence i
`
`If P
`
`Suffix
`
`I El
`
`I
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address 2
`
`Room 402, Ruvio II, 21-3, Sakura 1-chome
`
`City
`
`I tsukuba-shi, lbaraki
`I ro5-ooo3
`Postal Code
`Inventor ~
`Legal Name
`
`I State/Province
`I ~p
`I Countryi
`
`11
`
`I Remove
`
`I
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`I El fr'ouhei
`
`Residence Information (Select One)
`
`t,ATOU
`I
`US Residency @ Non US Residency
`
`City
`
`[sukuba-shi, lbaraki
`
`IICountry of Residence i
`
`Active US Military Service
`
`If P
`
`Suffix
`
`I El
`
`I
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address 2
`
`Room 401, Ruvio II, 21-3, Sakura 1-chome
`
`City
`
`I If sukuba-shi, lbaraki
`I ~05-0003
`Postal Code
`
`Inventor b
`
`Legal Name
`
`EFSWeb2.2.13
`
`I State/Province
`I µp
`I Countryi
`
`11
`
`I Remove
`
`I
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`I El Jshin'ichi
`
`Residence Information (Select One)
`
`lfAKEDA
`I
`US Residency @ Non US Residency
`
`Active US Military Service
`
`City
`
`rodaira-shi, Tokyo
`
`IICountry of Residence i
`
`l~P
`
`Suffix
`
`I El
`
`I
`
`Mailing Address of Inventor:
`
`Address 1
`
`~o National Center of Neurology and Psychiatry
`
`Address 2
`1-1, Ogawahigashicho 4-chome
`I f<odaira-shi, Tokyo
`City
`I 1181-8551
`Postal Code
`Inventor ~
`Legal Name
`
`I State/Province
`I ~p
`I Countryi
`
`11
`
`I Remove I
`
`Prefix Given Name
`
`Middle Name
`
`Family Name
`
`I El lfetsuya
`
`Residence Information (Select One)
`
`f'JAGATA
`I
`US Residency @ Non US Residency
`
`Active US Military Service
`
`City
`
`rodaira-shi, Tokyo
`
`IICountry of Residence i
`
`l~P
`
`Suffix
`
`I El
`
`I
`
`Mailing Address of Inventor:
`
`Address 1
`
`~o National Center of Neurology and Psychiatry
`
`Address 2
`1-1, Ogawahigashicho 4-chome
`I f<odaira-shi, Tokyo
`City
`Postal Code
`1 1181-8551
`
`I State/Province
`I ~p
`I Countryi
`All Inventors Must Be Listed - Additional Inventor Information blocks may be
`generated within this form by selecting the Add button.
`
`11
`
`I Add
`
`I
`
`Correspondence Information:
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`)55694
`
`Email Address
`
`DBRIPDocket@dbr.com
`
`I
`
`I Add Email
`
`I
`
`I Remove Email I
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Application Information:
`
`Title of the Invention
`
`I\NTISENSE NUCLEIC ACIDS
`
`Attorney Docket Number 1209658-0001-08-US-590121
`
`Application Type
`
`Non provisional
`
`Subject Matter
`
`Utility
`
`I Small Entity Status Claimed □
`
`.
`.
`
`Total Number of Drawing Sheets (if any)
`Filing By Reference:
`Only complete this section when filing an application by reference under 35 U.S.C. 111 (c) and 37 CFR 1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`I Suggested Figure for Publication (if any) 11
`
`1119
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`;_
`
`Publication Information:
`Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`□
`Request Not to Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`□
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`
`• Customer Number
`
`I
`
`US Patent Practitioner lo Limited Recognition (37 CFR 11.9)
`
`Customer Number
`
`~55694
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Domestic Benefit/National Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number" field blank.
`
`Prior Application Status
`
`!='ending
`
`.
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`~019-06-24
`I Remove I
`Issue Date
`(YYYY-MM-DD)
`
`Patent Number
`
`Filing Date
`(YYYY-MM-DD)
`
`~017-06-12
`
`110329319
`
`Filing Date
`(YYYY-MM-DD)
`
`Patent Number
`
`~019-06-25
`I Remove I
`Issue Date
`(YYYY-MM-DD)
`
`. 16449537
`.
`
`I
`
`Continuation of
`
`Prior Application Status Patented
`Application
`Number
`
`Continuity Type
`
`116449537
`
`pontinuation of
`
`Prior Application Status
`
`!='atented
`
`Application
`Number
`
`Continuity Type
`
`115619996
`
`pontinuation of
`
`Prior Application Status
`
`!='atented
`
`Application
`Number
`
`Continuity Type
`
`114615504
`
`pontinuation of
`
`Prior Application Status
`
`t=xpired
`
`Prior Application
`Number
`I· 115619996
`
`.
`
`Prior Application
`Number
`I· 114615504
`
`.
`
`Prior Application
`Number
`I· 113819520
`
`.
`
`~015-02-06
`
`~708361
`
`Filing Date
`(YYYY-MM-DD)
`
`Patent Number
`
`~013-04-10
`
`~079934
`
`~017-07-18
`I Remove I
`Issue Date
`(YYYY-MM-DD)
`
`~015-07-14
`I Remove I
`Filing or 371 (c) Date
`(YYYY-MM-DD)
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`~3819520
`
`► 371 of international
`
`. PCT/JP2011/070318
`
`~011-08-31
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`I Add
`
`I
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (Poxi the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the POX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1 ).
`
`Application Number
`
`Countryi
`
`Filing Date (YYYY-MM-DD)
`
`J/010-196032
`
`EFS Web 2.2.13
`
`~p
`
`J/010-09-01
`
`I Remove I
`Access Codei (if applicable)
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Add
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`□ 16,2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph Bin subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Priority Document Exchange (PDXl - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1 ).
`
`B. Search Results from U.S. Application to EPO - Unless box Bin subsection 2 (opt-out of authorization) is checked,
`the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`D application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Tille 37 of CFR
`to have an assignment recorded by the Office.
`
`I Remove I
`Applicant
`11
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I Clear
`
`I
`
`• Assignee
`
`I
`Person to whom the inventor is obligated to assign.
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`I
`Person who shows sufficient proprietary interest
`
`I
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally Incapacitated Inventor: I
`
`1~1
`
`If the Applicant is an Organization check here.
`
`~
`I ~IPPON SHINYAKU CO., LTD.
`
`Organization Name
`
`Mailing Address Information For Applicant:
`
`Address 1
`
`Address 2
`
`City
`Country I ~P
`
`Phone Number
`
`Email Address
`
`14, Kisshoin Nishinosho Monguchicho, Minami-ku
`
`Kyoto-shi, Kyoto
`
`State/Province
`
`Postal Code
`
`Fax Number
`
`601-8550
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`I Add
`
`I
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Applicant b
`
`I Remove I
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`I Clear
`
`I
`
`@ Assignee
`
`I
`Person to whom the inventor is obligated to assign.
`
`I
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`ITI
`
`Legal Representative under 35 U.S.C. 117
`
`I
`Person who shows sufficient proprietary interest
`
`Joint Inventor
`
`Name of the Deceased or Legally Incapacitated Inventor: I
`
`If the Applicant is an Organization check here.
`
`[81
`
`Organization Name
`
`I ~ATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
`
`Mailing Address Information For Applicant:
`
`Address 1
`
`Address 2
`
`City
`Country I ~P
`Phone Number
`
`Email Address
`
`1-1, Ogawahigashicho 4-chome
`
`Kodaira-shi, Tokyo
`
`State/Province
`
`Postal Code
`
`187-8551
`
`Fax Number
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`I Add
`
`I
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title
`37 of CFR to have an assignment recorded by the Office.
`
`Assignee
`
`11
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`I Remove I
`[81
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Organization Name
`
`I ~IPPON SHINYAKU CO., LTD.
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`n4, Kisshoin Nishinosho Monguchicho, Minami-ku
`
`Address 1
`
`Address 2
`
`City
`
`Countryi
`
`I ~p
`Phone Number
`
`Email Address
`
`I I
`l<yoto-shi, Kyoto
`
`State/Province
`
`Postal Code
`
`601-8550
`
`Fax Number
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Add
`
`I
`
`I
`
`Assignee ~
`
`Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent
`application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`I Remove I
`~
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`Organization Name
`
`I ~ATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`City
`
`Countryi
`
`I ~p
`Phone Number
`
`Email Address
`
`n-1, Ogawahigashicho 4-chome
`
`11 l<odaira-shi, Tokyo
`
`State/Province
`
`Postal Code
`
`187-8551
`
`Fax Number
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Add
`
`I
`
`I
`
`EFS Web 2.2.13
`
`

`

`PTO/AIN14 (02-18)
`Approved for use through 11/30/2020. 0MB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`209658-0001-08-US-590121
`
`Application Number
`
`Title of Invention
`
`ANTISENSE NUCLEIC ACIDS
`
`Signature:
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b ). However, if this Application
`Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in
`subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must
`also be signed in accordance with 37 CFR 1.14(c).
`This Application Data Sheet must be signed by a patent practitioner if one or more of the applicants is a juristic
`entity (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a
`patent practitioner, all joint inventors who are the applicant, or one or more joint inventor-applicants who have been given
`power of attorney (e.g., see US PTO Form PTO/AIA/81) on behalf of all joint inventor-applicants.
`See 37 CFR 1.4(d) for the manner of making signatures and certifications.
`
`Remove
`
`Signature
`
`I,zhengyu Feng/
`
`First Name
`
`~hengyu
`
`I Last Name I f eng
`
`Date (YYYY-MM-DD) 12019-12-12
`
`Registration Number
`
`~6816
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`I Add
`
`I
`
`This collection of information is required by 37 CFR 1. 76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of lime you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.13
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent
`application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information
`is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and
`Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S.
`Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of
`the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy
`Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of
`Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative
`tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom
`the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
`
`2.
`
`3
`
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform
`a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C.
`552a(m).
`
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use,
`to the International Bureau of the World Intellectual Property Organization, pursuant to the PatentCooperationTreaty.
`
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181)
`and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an
`inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and
`programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of
`records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about
`individuals.
`
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C.
`122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1. 14, as a routine use,
`to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes
`aware of a violation or potential violation of law or regulation.
`
`EFSWeb2.2.13
`
`

`

`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Docket No.: 209658-0001-08-US-590121
`(PATENT)
`
`In re Patent Application of:
`Naoki WATANABE et al.
`
`Continuation Application of
`Prior Application No.: 16/449,537
`Prior Application Filed: June 24, 2019
`
`Continuation Filed: Concurrently Herewith
`
`For: ANTISENSE NUCLEIC ACIDS
`
`Confirmation No.: Unassigned
`
`Group Art United: 1635
`(Prior Application)
`
`Examiner: Sean McGarry
`(Prior Application)
`
`FIRST PRELIMINARY AMENDMENT
`
`MS NEW
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Dear Sir:
`
`Prior to examination on the merits, please amend the above-identified U.S. patent
`
`application as follows:
`
`Amendments to the Specification begin on page 2.
`
`Amendments to the Claims begin on page 3.
`
`Remarks begin on page 5.
`
`121471652.1
`
`

`

`Application No. Not Yet Assigned
`Amendment dated December 12, 2019
`First Preliminary Amendment
`
`Docket No.: 209658-0001-08-US-590121
`Page2
`
`AMENDMENTS TO THE SPECIFICATION
`
`Please insert the following paragraph on page 1 of the specification before the section
`
`entitled "TECHNICAL FIELD":
`
`CROSS REFERENCE TO RELATED APPLICATIONS
`
`This application is a Continuation of copending Application No. 16/449,537 (allowed),
`
`filed June 24, 2019, which is a Continuation of Application No. 15/619,996, filed June 12, 2017
`
`(now U.S. Patent No. 10,329,319 issued June 25, 2019), which is a Continuation of Application
`
`No. 14/615,504, filed February 6, 2015 (now U.S. Patent No. 9,708,361 issued July 18, 2017),
`
`which is a Continuation of Application No. 13/819,520, filed April 10, 2013 (now U.S. Patent
`
`9,079,934 issued July 14, 2015), which is a PCT National Stage of PCT/JP2011/070318 filed
`
`August 31, 2011, which claims priority to JP Application No. 2010-196032 filed September 1,
`
`2010, all of which are incorporated by reference in their entireties.
`
`SEQUENCE LISTING
`
`The instant application contains a Sequence Listing which has been submitted in ASCII
`
`format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy,
`
`created on December 9, 2019 is named 209658_0001_08_US_590121_ST25.txt and is 24,765
`
`bytes in size.
`
`121471652.1
`
`

`

`Application No. Not Yet Assigned
`Amendment dated December 12, 2019
`First Preliminary Amendment
`
`Docket No.: 209658-0001-08-US-590121
`Page 3
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims will replace all prior versions, and listings, of the claims in the
`
`application:
`
`LISTING OF CLAIMS
`
`Claim 1. (Previously Amended): An antisense oligomer which causes skipping of the
`
`53rd exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to
`
`any one of the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides
`
`from the 5' end of the 53rd exon in the human dystrophin gene.
`
`Claim 2. (Original): The antisense oligomer according to claim 1, which is an
`
`oligonucleotide.
`
`Claim 3. (Original): The antisense oligomer according to claim 2, wherein the sugar
`
`moiety and/or the phosphate-binding region of at least one nucleotide constituting the
`
`oligonucleotide is modified.
`
`Claim 4. (Original): The antisense oligomer according to claim 3, wherein the sugar
`
`moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH
`
`group is replaced by any one selected from t